Agilent Plans Expansion of Oligo Manufacturing Capacity

Published on: 

Agilent Technologies announces plans to build a new oligo manufacturing facility in Colorado that will double current capacity.

Agilent Technologies announced on Aug. 9, 2106 that the company has acquired 20 acres in Weld County, CO, on which it plans to build a pharmaceutical manufacturing facility that will more than double its commercial manufacturing capacity for nucleic acid APIs. The expansion will add 150–200 jobs, the company reports.

"The products manufactured at this site will be used by our customers to improve the lives of patients suffering from a variety of diseases," said Skip Thune, general manager of the company's Nucleic Acids Solutions Division in a press statement. "At Agilent, we are committed to meeting the ever-increasing needs of our customers for oligonucleotides."

Agilent's 65,000-sq.-ft. facility in Boulder, CO, manufactures oligo APIs for clinical trials. Capabilities include four synthesis/purification trains and two lyophilization units. A commercial GMP plant expansion was completed in 2010 and can produce multi-kilo lots of late-stage clinical materials, as reported on the company website.


Source: Agilent Technologies